BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis. 2012;30:477-482. [PMID: 23108303 DOI: 10.1159/000341695] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 He C, Peng W, Li C, Wen TF. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine (Baltimore) 2017;96:e6606. [PMID: 28422855 DOI: 10.1097/MD.0000000000006606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
3 Yin K, Xia X, Rui K, Wang T, Wang S. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression. Front Oncol 2020;10:610104. [PMID: 33384962 DOI: 10.3389/fonc.2020.610104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rapisarda V, Loreto C, Malaguarnera M, Ardiri A, Proiti M, Rigano G, Frazzetto E, Ruggeri MI, Malaguarnera G, Bertino N, Malaguarnera M, Catania VE, Di Carlo I, Toro A, Bertino E, Mangano D, Bertino G. Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol 2016; 8(13): 573-590 [PMID: 27168870 DOI: 10.4254/wjh.v8.i13.573] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
5 De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Berretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One 2015;10:e0117420. [PMID: 25700262 DOI: 10.1371/journal.pone.0117420] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
6 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
7 Zhang Q, Huang H, Zheng F, Liu H, Qiu F, Chen Y, Liang CL, Dai Z. Resveratrol exerts antitumor effects by downregulating CD8+CD122+ Tregs in murine hepatocellular carcinoma. Oncoimmunology 2020;9:1829346. [PMID: 33150044 DOI: 10.1080/2162402X.2020.1829346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yang Y, Yang L, Wang Y. [Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy]. Zhongguo Fei Ai Za Zhi 2021;24:112-23. [PMID: 33626853 DOI: 10.3779/j.issn.1009-3419.2021.101.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zhang GL, Zhao W. Recent progress in understanding the effect of interventional therapy for hepatic carcinoma on immune function. Shijie Huaren Xiaohua Zazhi 2012; 20(33): 3225-3230 [DOI: 10.11569/wcjd.v20.i33.3225] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Ehling J, Tacke F. Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2015; Jun 26. [Epub ahead of print]. [PMID: 26123664 DOI: 10.1016/j.canlet.2015.06.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
11 Li XF, Dai D, Song XY, Liu JJ, Zhu L, Zhu X, Ma W, Xu W. A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. Oncol Lett 2017;13:3291-8. [PMID: 28529568 DOI: 10.3892/ol.2017.5808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
12 Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293 [PMID: 31148900 DOI: 10.3748/wjg.v25.i19.2279] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 63] [Article Influence: 22.7] [Reference Citation Analysis]
13 Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013;2:e26468. [PMID: 24498546 DOI: 10.4161/onci.26468] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
14 Liu XL, Wang LJ, Zhang S, Li MG, Yu H, Jiang YY, Wang XB, Yang ZY. Characteristics of CD4+ and CD8+ T cells in peripheral blood of patients with HBV-related primary liver cancer of Qi-Yin deficiency type. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4264-4271 [DOI: 10.11569/wcjd.v24.i31.4264] [Reference Citation Analysis]
15 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
16 Li X, Peng J, Pang Y, Yu S, Yu X, Chen P, Wang W, Han W, Zhang J, Yin Y, Zhang Y. Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. Sci Rep 2015;5:14757. [PMID: 26437631 DOI: 10.1038/srep14757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
17 Han Q, Zhao H, Jiang Y, Yin C, Zhang J. HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape. Cells. 2019;8. [PMID: 31181729 DOI: 10.3390/cells8060558] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
18 Liu LZ, Zhang Z, Zheng BH, Shi Y, Duan M, Ma LJ, Wang ZC, Dong LQ, Dong PP, Shi JY, Zhang S, Ding ZB, Ke AW, Cao Y, Zhang XM, Xi R, Zhou J, Fan J, Wang XY, Gao Q. CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology 2019;69:143-59. [PMID: 30070719 DOI: 10.1002/hep.30134] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 19.3] [Reference Citation Analysis]
19 Macedo C, Tran LM, Zahorchak AF, Dai H, Gu X, Ravichandran R, Mohanakumar T, Elinoff B, Zeevi A, Styn MA, Humar A, Lakkis FG, Metes DM, Thomson AW. Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients. Am J Transplant 2021;21:2372-86. [PMID: 33171019 DOI: 10.1111/ajt.16393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
20 Wang XF, Korangy F. Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC. Hepatology 2014;60:1461-2. [PMID: 24954163 DOI: 10.1002/hep.27271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer 2019;120:16-25. [PMID: 30413826 DOI: 10.1038/s41416-018-0333-1] [Cited by in Crossref: 145] [Cited by in F6Publishing: 157] [Article Influence: 36.3] [Reference Citation Analysis]